Keyphrases
Allergic Reaction
11%
Apoptosis
9%
Axillary Lymph Node Dissection
41%
Axillary Lymph Node Metastasis
9%
Bevacizumab
19%
Blue Dye
11%
Bone Marrow Progenitor Cells
9%
Breast
15%
Breast Cancer
64%
Breast Carcinoma
33%
Cape
22%
Carboplatin
19%
Complete Response Rate
14%
Cyclophosphamide
11%
Doxorubicin
11%
Extent of Disease
11%
Greasy Wool
9%
Growers
12%
High Prices
19%
High Risk
13%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Isosulfan Blue
11%
Lobular Carcinoma in Situ
12%
Local Recurrence
20%
Locally Recurrent
9%
Lymphovascular Invasion
18%
Magnetic Resonance Imaging
12%
Male Breast Carcinoma
19%
Metastasis
17%
Metastatic Breast Cancer
9%
Mohair
29%
Neoadjuvant Chemotherapy
12%
Nodal Metastasis
16%
Node-positive
18%
Pathological Complete Response
19%
Patient Selection
9%
Patients with Breast Cancer
16%
Positive Sentinel Lymph Node
13%
Positivity Rate
9%
Pre-metastatic Niche
19%
Primary Prevention
9%
Reoperative
29%
Sentinel Lymph Node
40%
Sentinel Lymph Node Biopsy
69%
Sentinel Lymph Node Mapping
19%
South Africa
13%
South African
13%
Triple-negative Breast Cancer
19%
Tumor
16%
Vascular Endothelial Growth Factor Receptor (VEGFR)
9%
Medicine and Dentistry
Allergic Response
11%
Arm
9%
Aromatase
9%
Atypical Hyperplasia
9%
Axilla
5%
Axillary Lymph Node
38%
Bevacizumab
9%
Biopsy Technique
17%
Breast Cancer
100%
Breast Carcinoma
62%
Breast Tumor
9%
Carboplatin
9%
Clinical Stage
5%
Cyclooxygenase 2
9%
Disease
12%
Event Free Survival
7%
Flexibility
9%
Fluorodeoxyglucose F 18
9%
Health Care Cost
9%
Intraductal Carcinoma
9%
Isosulfan Blue
11%
Lobular Carcinoma in Situ
9%
Lymph Node
8%
Lymph Node Metastasis
9%
Lymphedema
9%
Lymphovascular Invasion
13%
Magnetic Resonance Imaging
9%
Male Breast
19%
Malignant Neoplasm
30%
Mammography
5%
Metastatic Carcinoma
22%
Minimal Residual Disease
7%
Neoadjuvant Chemotherapy
9%
Neoplasm
30%
Nodal Metastasis
10%
Odds Ratio
7%
Patient History of Mastectomy
9%
Positron Emission Tomography
9%
Pulmonary Sequestration
9%
Recurrent Disease
37%
Retroperitoneal Lymph Node Dissection
30%
Sentinel Lymph Node
70%
Sentinel Lymph Node Biopsy
73%
Sentinel Node
9%
Surgery
19%
Thoracoscopy
6%
Triple Negative Breast Cancer
9%
Tumor Cell
5%
Tumor Recurrence
9%
Vasculotropin Receptor 1
9%